These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 16810452)

  • 1. Studying and evaluating pharmaceutical policy--becoming a part of the policy and consultative process.
    Almarsdóttir AB; Traulsen JM
    Pharm World Sci; 2006 Feb; 28(1):6-12. PubMed ID: 16810452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The argument for pharmaceutical policy.
    Traulsen JM; Almarsdóttir AB
    Pharm World Sci; 2005 Feb; 27(1):7-12. PubMed ID: 15861928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research evidence and policy: qualitative study in selected provinces in South Africa and Cameroon.
    Naude CE; Zani B; Ongolo-Zogo P; Wiysonge CS; Dudley L; Kredo T; Garner P; Young T
    Implement Sci; 2015 Sep; 10():126. PubMed ID: 26334760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical policy and the lay public.
    Traulsen JM; Almarsdóttir AB
    Pharm World Sci; 2005 Aug; 27(4):273-7. PubMed ID: 16228621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational use of medicines--an important issue in pharmaceutical policy.
    Almarsdóttir AB; Traulsen JM
    Pharm World Sci; 2005 Apr; 27(2):76-80. PubMed ID: 15999915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical policy and the pharmacy profession.
    Traulsen JM; Almarsdóttir AB
    Pharm World Sci; 2005 Oct; 27(5):359-63. PubMed ID: 16341741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Examining the use of health systems and policy research in the health policymaking process in Israel: views of researchers.
    Ellen ME; Lavis JN; Shemer J
    Health Res Policy Syst; 2016 Sep; 14(1):66. PubMed ID: 27585630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges to pharmaceutical policymaking: lessons from Australia's national medicines policy.
    Lipworth W; Doran E; Kerridge I; Day R
    Aust Health Rev; 2014 May; 38(2):160-8. PubMed ID: 24589424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Policymaking through a knowledge lens: Using the embodied-enacted-inscribed knowledge framework to illuminate the transfer of knowledge in a mental health policy consultation process - A South African case study.
    Marais DL; Petersen I; Quayle M
    PLoS One; 2021; 16(1):e0244940. PubMed ID: 33439892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promotion of evidence-informed health policymaking in Nigeria: bridging the gap between researchers and policymakers.
    Uneke CJ; Ezeoha AE; Ndukwe CD; Oyibo PG; Onwe F
    Glob Public Health; 2012; 7(7):750-65. PubMed ID: 22394290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of research findings for health policy making and practice: evidence from three case studies in Bangladesh.
    Walugembe DR; Kiwanuka SN; Matovu JK; Rutebemberwa E; Reichenbach L
    Health Res Policy Syst; 2015 May; 13():26. PubMed ID: 26016797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Community pharmacists' perceptions about pharmaceutical care of OTC western medicine: a survey in Harbin of China.
    Song M; Ung CO; Hu H; Wang Y
    Int J Clin Pharm; 2015 Dec; 37(6):1014-20. PubMed ID: 26286338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decision-makers and the usefulness of research evidence in policy implementation--a case study from Lao PDR.
    Tomson G; Paphassarang C; Jönsson K; Houamboun K; Akkhavong K; Wahlström R
    Soc Sci Med; 2005 Sep; 61(6):1291-9. PubMed ID: 15970238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Issues and Prospects from the OTC Industry vis a vis Pharmaceutical Education and OTC Medicines].
    Nishizawa M
    Yakugaku Zasshi; 2016; 136(7):955-63. PubMed ID: 27374957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanding the role of community pharmacists: policymaking in the absence of policy-relevant evidence?
    Mossialos E; Naci H; Courtin E
    Health Policy; 2013 Jul; 111(2):135-48. PubMed ID: 23706523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimethod research into policy changes in the pharmacy sector--the Nordic case.
    Almarsdóttir AB; Traulsen JM
    Res Social Adm Pharm; 2009 Mar; 5(1):82-90. PubMed ID: 19285293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A research roadmap for complementary and alternative medicine - what we need to know by 2020.
    Fischer F; Lewith G; Witt CM; Linde K; von Ammon K; Cardini F; Falkenberg T; Fønnebø V; Johannessen H; Reiter B; Uehleke B; Weidenhammer W; Brinkhaus B
    Forsch Komplementmed; 2014; 21(2):e1-16. PubMed ID: 24851850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translating tuberculosis research into global policies: the example of an international collaboration on diagnostics.
    Ramsay A; Steingart KR; Cunningham J; Pai M
    Int J Tuberc Lung Dis; 2011 Oct; 15(10):1283-93. PubMed ID: 22283885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.